AU Patent

AU2011329233A1 — NAMPT and ROCK inhibitors

Assigned to AbbVie Deutschland GmbH and Co KG · Expires 2013-05-23 · 13y expired

What this patent protects

Disclosed are compounds of formula (1c) which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds a…

USPTO Abstract

Disclosed are compounds of formula (1c) which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2011329233A1
Jurisdiction
AU
Classification
—
Expires
2013-05-23
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Deutschland GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.